European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) (ENERGIB)

AstraZeneca

Status: Completed

Conditions: Gastrointestinal Hemorrhage; Gastrointestinal Ulcer; Non-variceal Upper Gastrointestinal Bleeding

Study type: Observational

Funder types: Industry

Identifiers

NCT00797641

NIS-GEU-DUM-2008/2

Details and patient eligibility

About

The aim of this study is to assess the current management strategies in a pan-European "real-life" setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.

Enrollment: 2,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted to the hospital or inpatients with an overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical/laboratory evidences of acute blood loss from the upper GI tract
• Evidence that an upper GI endoscopy was performed
• The complete medical record is available for study related hospitalization.

Exclusion criteria

• NA

Trial design

2,500 participants in 1 patient group

1

Description:

Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract